|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout显示文摘 | Becker MA Schumacher HR Wortmann RL | 2005 | NEnglJMed2005，353，23： | 1 |
| 2 | Dermatomyositis显示文摘 | Callen JP Wortmann RL | 2006 | Clin Dermatol2006，24，5： | 1 |
| 3 | Gout and hyperuricemia显示文摘 | Wortmann RL | 2002 | Curr Opin Rheumatol2002，14，3： | 1 |
| 4 | Febuxostat compared with allopurinol in patients with hyperuricemia and gout 显示文摘 | Becker MA Schumacher HR Wortmann RL | 2005 | New En J Med2005，353，： | 1 |
| 5 | Gout and hyperuricemia显示文摘 | Wortmann RL | 2002 | Cur Opin Rheumatol2002，14，： | 1 |
| 6 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout :A 28 - week, phase Ⅲ, ran- domized, double - blind, parallel - group trial 显示文摘 | Schumacher JRHR Becker MA Wortmann RL | 2008 | Arthritis Care Res2008，59，： | 1 |
| 7 | Differentiating idiopathic inflammatory myopathies from metabolic myopathies显示文摘 | Wortmann RL DiMauro S | 2002 | Rherm Dis Clin N Am2002，28，： | 1 |
| 8 | Gout and hyperuricemia 显示文摘 | Wortmann RL | 2002 | Curr Opin Rheumatol2002，14，3： | 1 |
| 9 | The management of gout:It should be crystal clear显示文摘 | Wortmann RL | 2006 | J Rheumatol2006，33，： | 1 |
| 10 | Gout therapeutics:new drugs for an old disease显示文摘 | Burns CM Wortmann RL | 2011 | Lancet2011，377，9760： | 1 |
| 11 | Effect ofprophylaxis on gout flares after the initiation of urate-loweringtherapy: analysis of data from three phase III trials 显示文摘 | Wortmann RL Macdonald PA Hunt B | 2010 | ClinTher2010，32，14： | 1 |
| 12 | Effects of fe-buxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout:a28-week,phaseⅢ,ran-domized,double-blind,parallel-group trial显示文摘 | Schumacher HR Jr Becker MA Wortmann RL | 2008 | Arthritis Rheum2008，59，11： | 1 |
| 13 | Gout and hyperuricemia 显示文摘 | Wortmann RL | 2002 | Curt Opin Rheumatol2002，14，3： | 1 |
| 14 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase ill , randomized, double-blind, parallel-group trial 显示文摘 | Schumacher HR Becker MA Wortmann RL | 2008 | Arthritis Rheum2008，59，11： | 1 |
| 15 | Feb uxostat,a novel nonpurine selective inhibitor of xanthine oxidase:a twenty-eight-day,multicenter,phase II,randomized,double-blind,placebo-controlled,dose-response clinical trial examining safety and efficacy in patients with gout显示文摘 | Becker MA Schumacher HR Wortmann RL MacDonald PA Palo WA Eustace D | 2005 | Arthritis Rheum2005，52，： | 1 |
| 16 | Hyperuricemia and gout:new concepts indiagnosis and management 显示文摘 | Doghramji PP Wortmann RL | 2012 | Postgrad Med2012，124，6： | 1 |
| 17 | Febuxostat com- pared with allopurinol in patients with hyperuricemia and gout 显示文摘 | Becker MA Schumacher HR Wortmann RL | 2005 | N Engl J Med2005，353，： | 1 |
| 18 | Management of gout in older adults: barriers to optimal control显示文摘 | HOSKISON KT WORTMANN RL | 2007 | Drugs Aging2007，24，1： | 1 |
| 19 | Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase m, randomized, double-blind, parallel-group trial 显示文摘 | SCHUMACHER HR BECKER MA WORTMANN RL | 2008 | Arthritis Rheumatism2008，59，11： | 1 |
| 20 | Effect of prophylaxis on gout flares after the initiation of urate lowering therapy:analysis of data from three phase III trials 显示文摘 | Wortmann RL Macdonald PA Hunt B | 2010 | Clin Ther2010，32，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员